The Science
Clinical evidence, trial design, follow-up, safety, and the study choices that shape later access decisions.
Clinical evidence starts the access case, but it does not finish it. Regulators, payers, clinicians, and service planners all read the same trials through different questions.
For psychedelic therapies, the study design matters because the intervention includes more than a molecule: preparation, supervised dosing, monitoring, integration, trained staff, and a controlled setting.
Use this section to understand which evidence supports approval, which evidence supports reimbursement, and which gaps may have to be answered after launch.
Guides and tools
Clinical Development of Psychedelic Therapies
How psychedelic trial design choices shape approval, HTA review, reimbursement, service delivery, and patient access.
Trial Follow-Up vs HTA Horizon
A visual explanation of why pivotal endpoints, observed follow-up, and HTA model horizons answer different questions for high-touch psychedelic therapies.
Trial Design Choices That Become Access Risks
A practical map of the protocol choices that can support approval while still leaving payer, delivery, or access questions unresolved.
Further reading
PsyPal Guidance Paper (Version 5)
Cross-country implementation and evidence recommendations from the PsyPal consortium.
PsyPal Consortium | 26 Mar 2026 | EU | Guidance | Reviewed 17 Apr 2026
Psychedelic Drugs: Considerations for Clinical Investigations (Draft Guidance)
guidance source relevant to the science.
US Food and Drug Administration (FDA) | 23 Jun 2023 | US | Guidance | Reviewed 17 Apr 2026
Guideline on clinical investigation of medicinal products in the treatment of depression (Rev.3)
guidance source relevant to the science.
European Medicines Agency (EMA) | 15 Sept 2023 | EU | Guidance | Reviewed 17 Apr 2026
E10 Choice of Control Group and Related Issues in Clinical Trials
guidance source relevant to the science.
US Food and Drug Administration (FDA) | 1 Jan 2001 | US | Guidance | Reviewed 17 Apr 2026
NICE real-world evidence framework (ECD9)
guidance source relevant to the science.
National Institute for Health and Care Excellence (NICE) | 23 Jun 2022 | UK | Guidance | Reviewed 17 Apr 2026